Monoclonal antibodyFDA-approvedSecond-line
Vectibix
Generic name: panitumumab
How it works
Panitumumab binds to the EGFR on cancer cells, blocking growth signals and promoting cell death.
Cancer types
Colorectal Cancer— EGFR-expressing
Efficacy
In clinical trials, patients treated with Vectibix had improved response rates compared to those receiving best supportive care.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pancreatic Cancer Trial Examines Chemotherapy with or without Panitumumab | Pancreatic Cancer | phase-3 | — | Source → |
| Panitumumab-IRDye800 Trial for Pancreatic Cancer Patients Undergoing Surgery | Pancreatic Cancer | phase-1 | — | Source → |
| Early Magnesium Supplementation Helps Manage Hypomagnesemia in Colorectal Cancer Patients | Colorectal Cancer | observational | The incidence of grade 3 or higher hypomagnesemia was significantly lower in the post-protocol group than in the pre-protocol group (3.3% vs. 30.0%). | Source → |
| New Cancer Treatment Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | The overall response rates were 30.2% for sotorasib 960 mg-panitumumab, 7.5% for sotorasib 240 mg-panitumumab, and 1.9% for investigator's choice. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.